Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis

Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis

Source: 
Endpoints
snippet: 

Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-human primate toxicology study. Now, years later and with a different delivery vehicle for its RNAi drugs, Arrowhead faces animal tox issues again in what could be another pivotal setback for its pipeline.